CONFIDENTIAL TREATMENT REQUESTED
Redacted Portions are indicated by [****] 


 


CONFIDENTIAL


 


PURCHASE
AGREEMENT


 


This PURCHASE AGREEMENT (this “Agreement”),
dated as of May 4th, 2011 (the “Effective Date”), is entered into by and between Atossa Genetics, Inc., a Delaware
corporation (“Buyer”), and Hologic Inc., a Delaware corporation (“Seller”). Buyer and Seller
are referred to herein as the “ Parties” and each individually as a “Party.”


 


WHEREAS, Seller owns all right, title
and interest in the Purchased Assets (as defined in Section 2.3) and wishes to sell to Buyer all right, title and interest in such
Purchased Assets, and Buyer desires to acquire from Seller all right, title and interest in the Purchased Assets, free and clear
of any and all Encumbrances.


 


NOW, THEREFORE, in consideration
of the foregoing and the representations, warranties, covenants and agreements herein contained, and other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:


 


Section
1.          DEFINITIONS


 


1.1.          “Bill
of Sale” shall mean a bill of sale in substantially the form and substance attached hereto as Exhibit A.


 


1.2.          “Combination
Product” shall mean any Product sold or transferred, or Service performed, in combination with one or more other products,
processes or services (including without limitation adjuvant, reagents and delivery systems that are used in performing a therapeutic
function) which are not Products or Services.


 


1.3.          “Docket”
shall mean Seller’s or its agent’s list or other means of tracking information relating to the prosecution and maintenance
of the Patent Rights throughout the world, including without limitation the names, addresses, email addresses and phone numbers
of prosecution counsel and agents, and information relating to deadlines, payments (including without limitation annuity and maintenance
fees) and filings, which list or other means of tracking information is current as of the Effective Date. The Docket shall also
include a list of all deadlines for upcoming actions with respect to the Patent Rights (including without limitation annuity, maintenance
fee and other deadlines) that shall become due within one year of the Effective Date.


 


1.4.          “Encumbrance”
shall mean any mortgage, pledge, lien, charge, encumbrance, license, defect as to title, security interest, claims, covenant, condition,
option, right or restriction of any kind or nature whatsoever.


 


1.5.          “Product”
shall mean, on a country-by-country basis, any product the manufacture, use, sale, offer for sale or import of which, but for Buyer’s
ownership of the Patent Rights, would infringe a Valid Claim of the Patent Rights in such country, which may include the Purchased
Device to the extent meeting the foregoing requirements.


 


1.6.          “Net
Sales” shall mean the gross amount collected by Buyer for sales of Products, or for the performance of Services, less
the following:


 


 (a)          discounts
(including cash, quantity and patient program discounts), retroactive price reductions, charge-back payments and rebates granted
to managed health care organizations or to federal, state and local governments, their agencies, and purchasers and reimbursers
or to trade customers;


 



    	 



    	 



    

 


PURCHASE
AGREEMENT


 


(b)          refunds
given, or amounts repaid or credited by reason of damaged goods, recalls, rejection or return;


 


(c)          any
taxes or other governmental charges levied on the production, sale, transportation, delivery, performance or use of a Product or
Service; and


 


(d)          transportation
costs and costs of insurance in transit.


 


In the event that a Product is sold or Service
is performed as part of a Combination Product, Net Sales, for the purposes of determining royalty payments on the Combination Product,
shall mean the gross amount collected for the Combination Product less the deductions set forth in clauses (a) - (d) above, multiplied
by a proration factor that is determined as follows:


 


(i)          If
all components of the Combination Product were sold or performed, as applicable, separately during the same or immediately preceding
Reporting Period, the proration factor shall be determined by the formula [A / (A+B)], where A is the average gross sales price
of all Product or Service components (as applicable) during such period when sold or performed separately from the other component(s),
and B is the average gross sales price of the other component(s) during such period when sold or performed separately from the
Product or Service components (as applicable); or


 


(ii)         If
all components of the Combination Product were not sold or performed separately during the same or immediately preceding Reporting
Period, the proration factor shall be determined by the Parties in good faith negotiations based on the relative value contributed
by each component.


 


1.7.          “Patent
Files” shall mean copies (or originals, where available to Seller or its agents) of the following to the extent comprising
or relating to the Patent Rights: (i) all patents, patent applications, assignments and correspondence to and from the United States
Patent and Trademark Office (“USPTO”) and any other foreign patent offices (whether or not to or from Seller); and
(ii) all files, records, workbooks (including without limitation laboratory notebooks) and other material information in the possession
or control of Seller or its agents, of which Seller is aware, as of the Effective Date.


 


1.8.          “Patent
Rights” shall mean:


 


 (a)          the
United States and international (non-United States) patents and patent applications relating to the ductal lavage business conducted
by Cytyc Corporation (other than those patents and patent applications listed in Exhibit B-2), and any other patents and
patent applications identified and listed on Exhibit B-1 and attached hereto;


 


 (b)          any
United States and international patents and patent applications claiming the benefit of or priority to one or more of the patents
and patent applications described in the foregoing clause (a), and any direct or indirect divisionals, continuations, continuation-in-part
applications and continued prosecution applications (and their relevant international equivalents) of the patent applications described
in the foregoing clause (a), and the resulting patents; and


 


 (c)          any
patents resulting from reissues, reexaminations or extensions (and their relevant international equivalents, including, without
limitation supplementary protection certificates) of the patents described in clauses (a) and (b) above.


 



    	2



    	 



    

 


PURCHASE
AGREEMENT


 


1.9.          “Person”
shall mean any natural person, corporation, general partnership, limited partnership, limited liability company, proprietorship,
other business organization, trust, union, association or governmental or regulatory authority or agency.


 


1.10.         “PMA”
shall mean a Premarket Approval Application filed with the Food and Drug Administration pursuant to 21 C.F.R. Part 814.


 


1.11.         “Purchased
Device” shall mean the product marketed by Seller under the Purchased Device Trademark for which Seller sought and obtained
Regulatory Approval pursuant to (a) PMA notifications for the following 510(k) numbers: K983867 (microcatheter), K993342 (aspirator)
and K001098 (dilator) and (b) a 510(k) Class I exemption (contour cover).


 


1.12.         “Purchased
Device Manufacturing Documentation” shall mean all written and electronic documentation, schematics, drawings, flow charts
and other material information which Seller used or uses to manufacture the Purchased Device, including the items listed in Exhibit
C.


 


1.13.         “Purchased
Device Marketing Material” shall mean all (a) material used in marketing or promoting the Purchased Device including
visual aids, advertisements, brochures, displays and presentation materials, (b) packaging materials used for the Purchased Device,
and (c) labels, package inserts and other matter affixed to any container or packaging used with the Purchased Device, including
the items listed in Exhibit D.


 


1.14.         “Purchased
Device Regulatory Documentation” shall mean all applications, registrations, licenses, authorizations and approvals,
all correspondence submitted to or received from regulatory authorities and all supporting documents and all clinical studies and
tests and other safety studies and tests, and all data contained in any of the foregoing, including all premarket approval notifications,
marketing authorizations, filings under the electronic product standards provisions of the United States Federal Food Drug and
Cosmetic Act, adverse event files, complaint files and manufacturing records, in each case that relate to the Purchase Device.


 


1.15.         “Purchased
Device Technology” shall mean, other than the Patent Rights and Purchased Device Regulatory Documentation, all data,
information, know-how, techniques, processes, methods, formulations, specifications, marketing plans and strategies, software (including
source code and related documentation), and other technology, including the Purchased Device Manufacturing Documentation and Purchased
Device Marketing Material (and all copyrights, trade secret rights and other intellectual property rights relating to any of the
foregoing), in each case that relate to the Purchased Device.


 


1.16.         “Purchased
Device Trademark” the trademark FIRSTCYTE, together with all goodwill symbolized thereby, and all registrations and applications
for registration thereof, including U.S. Registration No. 2,782,866 (the “Trademark Registration”).


 


1.17.         “Regulatory
Approval” shall mean the right with respect to a product to manufacture, sell or distribute such product, including in
the United States the approval by the FDA of a PMA and, in the case of any other country or territory, any necessary international
or foreign approvals.


 


1.18.         “Reporting
Period” shall begin on the first day of each calendar quarter and end on the last day of such calendar quarter.


 


1.19.         “Seller
Products” shall mean Seller’s products that are commercially marketed and distributed by Seller (other than in
its capacity as a reseller or other distributor) as of the Effective Date, substantially in the configurations marketed and distributed
by Seller as of the Effective Date.


 



    	3



    	 



    

 


PURCHASE
AGREEMENT


 


1.20.         “Seller
Future Products” shall mean Seller’s products that are commercially marketed and distributed by Seller (other than
in its capacity a reseller or other distributor) after the Effective Date and which substantially differ in configuration from
Seller Products marketed and distributed as of the Effective Date.


 


1.21.         “Service”
shall mean, on a country-by-country basis, any service the performance of which, but for Buyer’s ownership of the Patent
Rights, would infringe a Valid Claim of the Patent Rights in such country.


 


1.22.         “Third
Party” shall mean any Person other than Seller or Buyer.


 


1.23.         “Trademark
Assignment” shall mean a trademark assignment in substantially the form and substance attached hereto as Exhibit E.


 


1.24.         “Valid
Claim” shall mean a claim of an issued an unexpired patent which has not been revoked or held unenforceable or invalid
by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed
for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise.


 


Section
2.          PURCHASE AND SALE OF PATENT RIGHTS.


 


2.1.          Sale
of Patent Rights. Subject to the terms and conditions of this Agreement, Seller hereby sells, assigns, transfers, conveys and
delivers to Buyer, and Buyer purchases, acquires and accepts from Seller, all right, title and interest throughout the world in
and to the Patent Rights free and clear of any and all Encumbrances. Such assignment shall be effected by delivery of ten (10)
original copies of a duly executed Patent Assignment in the form attached hereto as Exhibit F (the “Patent Assignment”).


 


2.2.          Sale
of Additional Assets and Rights. Seller also hereby sells, assigns, transfers and conveys to Buyer all right, title and interest
in and to any and all:


 


(a)          inventions,
invention disclosures and discoveries described in any of the Patent Rights that (i) are included in any claim in the Patent Rights;
or (ii) are subject matter capable of being reduced to a patent claim in a reissue or reexamination proceeding relating to any
of the Patent Rights;


 


(b)          rights
to apply in any or all countries of the world for patents, certificates of invention, utility models or other governmental grants
or issuances of any type related to any of the Patent Rights and the inventions, invention disclosures and discoveries therein;


 


(c)          causes
of action (whether known or unknown or whether currently pending, filed or otherwise) and other enforcement rights under, or on
account of, any of the Patent Rights or the rights described in Section 2.2(b), including, without limitation, all causes of action
and other enforcement rights for damages, injunctive relief and any other remedies of any kind for past, current or future infringement;
and


 


(d)          other
than Seller’s rights to collect the Upfront Fee (as defined below) and royalties from Buyer as set forth in Section 2.4 and
SECTION 3, respectively, rights to collect royalties or other payments under or on account of any of the Patent Rights or any of
the foregoing (the assets and rights described in this Section 2.2 and the Patent Rights, collectively, the “Purchased
Patent Assets”).


 



    	4



    	 



    

 


PURCHASE
AGREEMENT


 


2.3.          Sale
of Purchased Device Assets.


 


(a)          Purchased
Device Assets. Subject to the terms and conditions of this Agreement, Seller hereby sells, assigns, transfers, conveys and
delivers to Buyer, and Buyer purchases, acquires and accepts from Seller, (i) all right, title and interest throughout the world
in and to the Purchased Device Technology, Purchased Device Regulatory Documentation and Purchased Device Trademark (including
the Trademark Registration) and (ii) all of Seller’s inventory of the Purchased Device (together with the Purchased Patent
Assets, collectively, the “Purchased Assets”).


 


(b)          Blocking
IP License. In addition, subject to the terms and conditions of this Agreement, Seller (on behalf of itself and its affiliates)
hereby grants to Buyer a non-exclusive, perpetual, worldwide, sublicensable license to research, develop, make use, sell, offer
for sale, import, commercialize and otherwise fully exploit the Purchased Device (and any modification, variation, revision, enhancement
or other improvement to the Purchased Device, including any new or expanded uses for the Purchased Device).


 


2.4.          Upfront
Fee. Within ten (10) days after the Effective Date, in partial consideration of Seller’s sale, assignment, transfer,
conveyance and delivery of the Purchased Assets to Buyer, Buyer will pay to Seller an upfront fee equal to [****] (“Upfront Fee”), by wire transfer in immediately available funds to
such account(s) as may be designated by Seller in writing.


 


2.5.          Delivery
of Assets. On the Effective Date, the Parties shall mutually execute and deliver to each other the Patent Assignment, Bill
of Sale and Trademark Assignment and, within ten (10) days after the Effective Date, Seller shall deliver or cause to be delivered
to Buyer the Patent Files and Docket. In addition, within thirty (30) days after the Effective Date, Seller shall deliver or cause
to be delivered to Buyer all of its Purchased Device inventory, all copies in its possession or control of tangible embodiments
of the Purchased Device Technology, and all copies in its possession or control of Purchased Device Regulatory Documentation (together
with all master copies of the foregoing), provided that Seller may retain a reasonable number of copies of the foregoing for archival
purposes. Further, Seller agrees to reasonably cooperate with Buyer and provide to Buyer reasonable technical, scientific, engineering
and other assistance and support necessary or reasonably useful to transfer to Buyer the Purchased Assets.


 


2.6.          Sales
and Transfer Taxes. Seller shall bear solely all sales, use, excise, value added and other transfer taxes and duties applicable
to the transfer of the Purchased Assets in connection with this Agreement. Any payment or reimbursement under this Section 2.6
shall be made within ten (10) business days after any such valid request for payment or reimbursement. For the avoidance of doubt,
Buyer shall bear the cost of recording the Patent Assignment in all governmental offices.


 


2.7.          Grantback
License. Subject to the terms and conditions of this Agreement, Buyer hereby grants to Seller a non-exclusive, perpetual, worldwide,
sublicensable, royalty-free license to make, use, sell, offer for sale and import Seller Products and Seller Future Products.


 


Section
3.          ROYALTIES.


 


3.1.          Royalties.


 


(a)          Royalties.
Subject to the terms and conditions of this Agreement, Buyer shall pay to Seller royalties, on a country-by-country and Product-by-Product
and Service-by-Service basis, for the period of time specified in Section 3.2(a), at the graduated royalty rates specified in the
following table with respect to Net Sales of Products and Services:


 



    	5



    	 



    

 


PURCHASE
AGREEMENT


 


	Aggregate Net Sales 
 of All Products and Services in a Calendar Year	 	Royalty Rate
	On such Net Sales up to [****]	 	[****]
	
        On such Net Sales above [****]

        [****]
		[****]
	On such Net Sales above [****]	 	[****]


  


3.2.          Royalty
Rate. The applicable royalty right shall be determined by reference to all Net Sales on which royalties are paid in a given
calendar year. By way of example, in a given calendar year, if the aggregate annual worldwide Net Sales for all Products and Services
for which royalties are due under this Section 3.1(a) were [****] under this Section 3.1(a) [****] this Agreement):[****]


 


(a)          Royalty
Term. The royalties due under Section 3.1(a) shall be payable on Net Sales from the first commercial sale of a Product or commercial
performance of a Service until, on a country-by-country basis, the expiration of the last to expire patent in such country within
the Patent Rights containing a Valid Claim covering such Product or Service.


 


(b)          Only
One Royalty. Only one royalty shall be due with respect to the sale of the same unit of Product or the performance of the same
Service. Only one royalty shall be due hereunder on the sale of a Product or performance of a Service even if the manufacture,
use, sale, offer for sale or importation of such Product or performance of such Service infringes more than one claim of tile Patent
Rights.


 


(c)          Royalty
Stacking. To the extent that Buyer obtains licenses to Third Party patent rights or other intellectual property in order to
practice any Patent Right or to make, use, sell, offer for sale, import, discover, develop, manufacture, derive, commercialize
or otherwise exploit any Products or Services, Buyer may deduct from any royalty due to Seller hereunder fifty percent (50%) of
the royalties due to Third Party(ies) on such patents or intellectual property up to an amount equal to fifty percent (50%) of
the royalties owed in any Reporting Period, with any excess Third Party royalties carried over into next succeeding Royalty Periods
until exhausted.


 


(d)          Royalty
Reduction. Should Seller market and sell Seller Future Products, the Buyer shall be entitled to reduce the royalty rate by
1% during the portion of each year that such Seller Future Products are sold.


 


(e)          Payment
Terms. All royalty payments under this Agreement should be made payable to “Hologic, Inc.” and sent to the address
identified in Section 6.9. All royalty payments due under this Agreement shall be payable in United States dollars. Any royalty
payments by Buyer that are not paid on or before the date such payments are due under this Agreement shall bear interest, to the
extent permitted by law, at two percentage points above the Prime Rate of interest as reported in the Wall Street Journal
on the date payment is due.


 


3.3.          Reports
and Records.


 


(a)          Reports.
Buyer shall report to Seller the date of first commercial sale of a Product or performance of a Service by Buyer within sixty (60)
days of occurrence. After the first commercial sale of a Product or performance of a Service by Buyer, Buyer shall deliver reports
to Seller within sixty (60) days after the end of each Reporting Period, containing information concerning the immediately preceding
Reporting Period, as follows: (i) the number of Products sold for which Net Sales accrue; (ii) the number of Services performed
for which Net Sales accrue (iii) the gross amount collected by Buyer for sales of Products, or for the performance of Services;
(iv) the calculation of Net Sales for the applicable Reporting Period, including a listing of applicable deductions; and (v) the
total royalty payable on Net Sales.


 



    	6



    	 



    

 


PURCHASE
AGREEMENT


 


(b)          Records.
Buyer shall maintain complete and accurate records relating to royalties payable to Seller hereunder. Buyer shall retain such records
for at least two (2) years following the end of the calendar year to which they pertain, during which time a certified, independent
public accountant selected by Seller and reasonably acceptable to Buyer shall have the right, at Seller’s expense, no more
than once every calendar year, to inspect such records during normal business hours to verify any reports and payments made. In
the event that any audit performed under this Section 3.3(b) reveals an underpayment in excess of ten percent (10%), Buyer shall
bear the full reasonable out-of-pocket cost of such audit and shall remit any amounts due to Seller within thirty (30) days of
receiving notice thereof from Seller.


 


(c)          Confidentiality.
The reports and records provided by Buyer hereunder shall be regarded as Buyer’s confidential information and Seller hereby
covenants that it shall not use or disclose any information included in such reports for any purpose other than determining whether
Buyer has complied with its royalty obligations under this Agreement. Seller further agrees that, until such time as such information
is no longer confidential through no fault of Seller, it shall maintain such reports and any information included therein and in
such records in strict confidence and treat such information in a manner at least as restrictive as its manner of treating its
own confidential information of similar nature and in any event not less than with a reasonable degree of care.


 


Section
4.          REPRESENTATIONS AND WARRANTIES.


 


4.1.          Seller
Representations and Warranties. As a material inducement to Buyer to enter into this Agreement and consummate the transactions
contemplated hereby, Seller hereby makes to Buyer the representations and warranties contained in this Section 4.1.


 


(a)          Authority,
Organization. Seller hereby represents and warrants to Buyer that (i) the execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby have been duly and validly authorized by all necessary action required on
the part of Seller and no other proceedings on the part of Seller are necessary to authorize this Agreement to which it is a party
or to consummate the transactions contemplated hereby, (ii) this Agreement has been duly and validly executed and delivered by
Seller and constitutes the legal, valid and binding agreement of Seller, enforceable against Seller in accordance with its terms,
and (iii) Seller is a Delaware corporation duly organized, validly existing and in good standing under the laws of the jurisdiction
under which it was formed.


 


(b)          Consents
and Approvals. No consent or approval of any other Person is required to be obtained by Seller for the execution, delivery
or performance of this Agreement or the performance by Seller of the transactions contemplated hereby.


 


(c)          Litigation.
To the best of Seller’s knowledge, there is no claim, litigation, suit, action, proceeding or investigation (whether at law
or equity, before or by any federal, state or foreign court, tribunal, commission, board, agency or instrumentality, or before
any arbitrator) pending or, threatened against Seller or involving any of the Purchased Assets, nor is there any judgment, decree,
injunction, rule or order of any court, governmental department, commission, agency, instrumentality or arbitrator outstanding
against Seller or involving any of the Purchased Assets. Without limiting the foregoing, no claim or demand of any other Person
has been made, or to the best of Seller’s knowledge, threatened, that challenges the rights of Seller in respect of any Patent
Right or the Purchased Device.


 



    	7



    	 



    

 


PURCHASE
AGREEMENT


 


(d)          Purchased
Assets.


 


(i)          Seller
owns all right, title and interest in and to all of the Purchased Assets, free and clear of any Encumbrance whatsoever. Neither
Seller nor, to the best of Seller knowledge, any Person having had any interest at any time in any of the Purchased Assets, has
assigned, transferred, licensed, pledged or otherwise encumbered any interest in any of the Purchased Assets or agreed to do so
(other than (A) for transfers of rights prior to the date of this Agreement, so long as Seller now holds all such rights, or (B)
as contemplated by this Agreement). Neither Seller nor any Person with any interest at any time in any of the Purchased Assets
has entered into any covenant not to compete or contract or agreement restricting the right to use or practice any of the Purchased
Assets in any market or geographic area or with or without any Person. To the best of Seller’s knowledge, the Purchased Assets
include all intellectual property rights and other rights necessary for Buyer to manufacture and, in the jurisdictions in which
it has obtained. Regulatory Approval, market the Purchased Device in the configuration in which it exists as of the Effective Date,
and the Patent Rights include all patents and patent applications owned or controlled by Seller or any of its affiliates relating
to ductal lavage.


 


(ii)         As
the result of the transactions contemplated hereby, Buyer will, as of the Effective Date, own all right, title and interest in
and to all of the Purchased Assets, free and clear of any and all Encumbrances whatsoever.


 


(e)          Patent
Rights.


 


(i)          To
the best of Seller’s knowledge, (A) Seller is not aware of any information that would form a reasonable basis for invalidating
or rendering unenforceable any claim in the Patent Rights (assuming in the instance of patent applications, for purposes of this
representation, that patents have issued), (B) no statement or assertion has been made by any Person that any such claim is invalid
or unenforceable and (C) no statement or assertion has been made by any Person that such Person is aware of any reasonable basis
as to the future invalidity or unenforceability of any such claim.


 


(ii)         The
Patent Rights have been properly prepared and filed and have been diligently pursued by Seller and all grant, issuance and maintenance
fees due have been paid when due through the Closing, and there are no defects in the filing or prosecution of the Patent Rights
that could cause either (A) the invalidity, unenforceability or lapse of any Patent Rights (including any patents that may issue
from the patent applications) or (B) patents not to issue from the patent applications. Seller has received assignment of the entire
right, title and interest in and to the Patent Rights from any and all inventors with respect thereto and/or any and all predecessors
in right without obligation for the payment of any further consideration whatsoever.


 


(iii)        To
the best of Seller’s knowledge, (A) no action has taken place (whether by the USPTO, any other foreign patent offices or
any Person), and no notice of or information with respect to any such pending or contemplated action has been issued, delivered
or made known to Seller or its counsel, that would affect, in any way, the Patent Rights or the prospects for the issuance of patents
in the near-term and (B) no events have occurred or are anticipated to occur that would cause an unreasonable delay in the issuance
of patents. All fees and assessments owed as of the Closing to the USPTO, any other foreign patent offices or any Person in respect
of the Patent Rights have been paid:


 



    	8



    	 



    

 


PURCHASE
AGREEMENT


 


EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS
AGREEMENT, BUYER ACKNOWLEDGES AND AGREES THAT UPON CLOSING THE SELLER SHALL SELL AND CONVEY TO BUYER AND BUYER SHALL ACCEPT THE
PURCHASED ASSETS BEING CONVEYED BY THE SELLER “AS IS, WHERE IS, WITH ALL FAULTS.” EXCEPT FOR THE REPRESENTATIONS AND
WARRANTIES CONTAINED IN THIS AGREEMENT, THE SELLER MAKES NO EXPRESS OR IMPLIED REPRESENTATIONS OR WARRANTIES OF ANY KIND, INCLUDING,
WITHOUT LIMITATION, ANY REPRESENTATIONS OR WARRANTIES AS TO THE CONDITION, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE
OF THE PURCHASED ASSETS OR THE PURCHASED DEVICE, THE INCOME DERIVED OR POTENTIALLY TO BE DERIVED FROM THE PURCHASED ASSETS OR THE
EXPENSES INCURRED OR POTENTIALLY TO BE INCURRED IN CONNECTION WITH THE PURCHASED ASSETS. SPECIFICALLY, EXCEPT FOR THE REPRESENTATIONS
AND WARRANTIES CONTAINED IN THIS AGREEMENT, SELLER MAKES NO WARRANTY OR REPRESENTATION (A) REGARDING THE VALIDITY OR SCOPE OF THE
PATENT RIGHTS, (B) THAT THE EXPLOITATION OF THE PATENT RIGHTS WILL NOT INFRINGE ANY PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS
OF A THIRD PARTY, AND (C) THAT ANY THIRD PARTY IS NOT CURRENTLY INFRINGING OR WILL NOT INFRINGE THE PATENT RIGHTS. BUYER HAS NOT
RELIED AND WILL NOT RELY ON, AND SELLER IS NOT LIABLE FOR OR BOUND BY, ANY EXPRESS OR IMPLIED WARRANTIES, GUARANTEES, STATEMENTS,
REPRESENTATIONS OR INFORMATION PERTAINING TO THE PURCHASED ASSETS OR RELATING THERETO MADE OR FURNISHED BY SELLER OR ITS REPRESENTATIVES,
TO WHOMEVER MADE OR GIVEN, DIRECTLY OR INDIRECTLY, ORALLY OR IN WRITING, EXCEPT AS EXPRESSLY STATED HEREIN.


 


4.2.          Buyer
Representations and Warranties. As a material inducement to Seller to enter into this Agreement and consummate the transactions
contemplated hereby, Buyer hereby represents and warrants to Seller that (a) the execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action required
on the part of Buyer and no other proceedings on the part of Buyer are necessary to authorize this Agreement to which it is a party
or to consummate the transactions contemplated hereby, (b) this Agreement has been duly and validly executed and delivered by Buyer
and constitutes the legal, valid and binding agreement of Buyer, enforceable against Buyer in accordance with its terms, and (c)
Buyer is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction under which it
was formed.


 


Section
5.          FURTHER ASSURANCES.


 


From time to time after the Closing, without
further consideration, Seller will, at Buyer’s expense, promptly execute and deliver such documents to Buyer and take such
additional action as Buyer may reasonably request in order to more effectively consummate the sale and purchase of the Purchased
Assets and to more effectively vest in Buyer good and marketable title to such ownership interest, including without limitation
all documents reasonably requested by Buyer to perfect and record the assignment and transfer of the Purchased Patent Assets, Purchased
Device Regulatory Documentation and other Purchased Assets to Buyer.


 


Section
6.          GENERAL.


 


6.1.          Governing
Law. All disputes, claims or controversies, arising out of this Agreement, or the negotiation, validity or performance of this
Agreement, or the transactions contemplated hereby shall be governed by and construed in accordance with the laws of the Commonwealth
of Massachusetts without regard to its rules of conflict of laws.


 



    	9



    	 



    

 


PURCHASE
AGREEMENT


 


6.2.          Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.


 


6.3.          Headings.
The section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.


 


6.4.          Entire
Agreement. This Agreement, including the exhibits referred to herein and the other writings specifically identified or contemplated
hereby, is complete, reflects the entire agreement of the Parties with respect to its subject matter, and supersedes all previous
written or oral negotiations, commitments and writings. No promises, representations, understandings, warranties and agreements
have been made by any of the Parties hereto except as referred to herein or in such schedules and exhibits or in such other writings;
and all inducements to the making of this Agreement relied upon by either Party hereto have been expressed herein or in such schedules
or exhibits or in such other writings.


 


6.5.          Amendments.
This Agreement may not be amended or modified, nor may compliance with any condition or covenant set forth herein be waived, except
by a writing duly and validly executed by each Party hereto, or in the case of a waiver, the Party waiving compliance.


 


6.6.          Assignment:
Binding Effect. No Party may assign this Agreement in whole or in part without the prior written consent of the other Party;
provided, however, that either Party may assign this Agreement without the written consent of the other Party to (a) one of its
Affiliates and (b) an entity succeeding to substantially all the assets and business of such Party by merger or purchase, provided
that such entity shall expressly assume all of such Party’s obligations under this Agreement by a writing delivered to the
other Party. For purposes hereof, “Affiliate” means, with respect to a Party, an entity which, directly or indirectly,
owns or controls, is owned or is controlled by or is under common ownership or control with such Party, and for those purposes
“control” means the power to direct the management or affairs of an entity, and “ownership” means the beneficial
ownership of 50% or more of the voting equity securities or other equivalent voting interests of the entity. Subject to the foregoing,
this Agreement shall be binding on the Parties and their successors and assigns.


 


6.7.          Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable
law, but if any provision of this Agreement shall be deemed prohibited or invalid under such applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, and such prohibition or invalidity shall not invalidate the remainder
of such provision or the other provisions of this Agreement.


 


6.8.          Publicity.


 


 (a)          Non-Disclosure
of Terms. Each Party shall hold in confidence and shall not disclose to any Third Party (other than their directors, employees,
legal counsel and accountants who, except in the case of legal counsel, are bound in writing by confidentiality obligations no
less restrictive than those set forth herein) the terms and conditions of this Agreement, except: (a) in order to comply with applicable
non-patent law (including any securities law or regulation or the rules of a securities exchange) and with judicial process if,
in the reasonable opinion of such Party’s counsel, such disclosure is necessary for such compliance, provided that such Party
shall notify the other Party of such Party’s intent to make any such disclosure sufficiently prior to making such disclosure
so as to allow such other of the Party adequate time to review and comment on such disclosure (it being understood that the disclosure
of the information set forth in Exhibit G with respect to this Agreement and the filing of a copy of this Agreement redacted by
Buyer, in each case pursuant to securities laws or regulations or the rules of a securities exchange, is hereby approved by Seller);
or (b) to a bona fide potential permitted assignee in connection with a proposed permitted assignment of this Agreement,
investment bankers, investors and lenders, and their directors, employees, legal counsel and accountants, provided such bona
fide potential permitted assignee must be bound prior to disclosure by confidentiality and non-disclosure restrictions at least
as restrictive as those set forth herein, and such investment bankers, investors and lenders must be bound prior to disclosure
by commercially reasonable obligations of confidentiality. The foregoing shall not, however, prohibit Buyer from recording the
Patent Assignment in any governmental office.


 



    	10



    	 



    

 


PURCHASE
AGREEMENT


 


6.9.          Notices.
Any notice, request, demand or other communication required or permitted hereunder shall be in writing and shall deemed to have
been duly given when received if personally delivered; when transmitted, if transmitted by telecopy, electronic or digital transmission
method; the day after it is sent if sent for next day of delivery to a domestic address by a recognized overnight delivery service.
All notices to a Party will be sent to the addresses set forth below or to such other address or person as such Party may designate
by notice to each other Party hereunder:


 


	  To Seller:	Hologic, Inc.
	 	250 Campus Drive
	 	Marlborough, MA 01752
	 	Attn: General Counsel
	 	Facsimile:  508-263-2959
	 	 
	 To Buyer:	Atossa Genetics, Inc.
	 	4105 E Madison St, Suite 320
	 	Seattle, WA 98112
	 	Attn: President
	 	Facsimile: 206-325-6087
	 	 
	 	[SIGNATURE PAGE FOLLOWS]


 



    	11



    	 



    

 


PURCHASE
AGREEMENT


 


IN WITNESS WHEREOF the Parties hereto have
caused this Agreement to be executed as of the date set forth above by their duly authorized representatives.


 


	 	SELLER:
	 	 
	 	Hologic Inc.
	 	 	 
	 	By:	//s// Tom Umbel
	 	 	 
	 	Name:	Tom Umbel
	 	 	 
	 	Title:	SVP, Business Development
	 	 	 
	 	BUYER:
	 	 
	 	Atossa Genetics, Inc.
	 	 	 
	 	By:	//s// Steven C. Quay
	 	 	 
	 	Name: 	Steven C. Quay MD, PhD
	 	 	 
	 	Title:	CEO & President


 



    	12



    	 



    

 


EXHIBIT
A


 


FORM OF
BILL OF SALE


 


[Attached]


 



    	 



    	 



    

 


BILL OF SALE


 


KNOW ALL MEN BY THESE PRESENTS as of May
4th, 2011, that the undersigned, Hologic Inc., a Delaware corporation (“Seller”), for valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, does hereby sell, transfer, assign, convey and deliver
to Atossa Genetics, Inc., a Delaware corporation (“Buyer”), and its successors and assigns, all rights, title
and interest of the Seller in, to and under the Purchased Assets, free and clear of all Encumbrances. All capitalized terms not
defined herein shall have the meanings ascribed to such terms in the Purchase Agreement, dated May 4th, 2011,
by and between the Seller and Buyer.


 


TO HAVE AND TO HOLD the aforesaid Purchased
Assets unto Buyer and its successors and assigns to and for its and their own proper use and benefit forever.


 


From time to time, the Seller shall, at
the request of Buyer and without further consideration, execute and deliver further instruments of transfer and assignment and
take such other actions as Buyer may reasonably require to effectively transfer and assign to, and vest in, Buyer all rights, title
and interest in, to and under the Purchased Assets.


 


This instrument shall inure to the benefit
of the parties hereto and their respective successors and assigns. It shall not be construed to create any third-party beneficiary
rights.


 


IN WITNESS WHEREOF, the undersigned have executed and delivered
this Bill of Sale as of the date first set forth above.


 


	SELLER:	 	BUYER:
	 	 	 
	Hologic Inc.	 	Atossa Genetics, Inc.
	 	 	 	 	 
	By:	//s// Tom Umbel	 	By:	//s// Steven C. Quay
	 	 	 	 	 
	Name: 	Tom Umbel	 	Name: 	Steven C. Quay MD, PhD
	 	 	 	 	 
	Title:	SVP, Business Development	 	Title:	CEO & President


 



    	 



    	 



    

 


EXHIBIT
B-1 


 


PATENT RIGHTS


 


	Docket No.	 	Country	 	Application No.	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 
	12.001011.3	 	EPC	 	99917356.0	 	1091685	 	Granted
	12.001011.3	 	France	 	99917356.0	 	1091685	 	Granted
	12.001011.3	 	Germany	 	699 38 898.8	 	1091685	 	Granted
	12.001011.3	 	Ireland	 	99917356.0	 	1091685	 	Granted
	12.001011	 	PCT	 	US99/07589	 	N/A	 	Expired
	12.001011.3	 	United Kingdom	 	9991735600	 	1091685	 	Granted
	12.001011	 	US	 	60/080,963	 	N/A	 	Expired
	12.001011.1	 	US	 	09/287,087	 	6336,904	 	Granted
	12.003011.4a	 	Australia	 	26319/00	 	763610	 	Granted
	12.003011.4b	 	Australia	 	26320/00	 	764777	 	Granted
	12.003011.4c	 	Australia	 	27406/00	 	766336	 	Granted
	12,0030I1.4d	 	Australia	 	2003-248031	 	N/A	 	Abandoned
	12.003011.4e	 	Australia	 	2003-259578	 	N/A	 	Abandoned
	12.003011.5a	 	Canada	 	2361122	 	N/A	 	Abandoned
	12.003011.5b	 	Canada	 	2361123	 	N/A	 	Abandoned
	12.003011.5c	 	Canada	 	2358971	 	N/A	 	Abandoned
	12.003011.3a	 	EPC	 	00904588.1	 	1144003	 	Granted
	12.003011.3a	 	EPC	 	00904589.9	 	N/A	 	Abandoned
	12.003011.3a	 	EPC	 	009057753	 	N/A	 	Abandoned
	12.003011.3a	 	France	 	00904588.1	 	1144003	 	Granted
	12.003011.3a	 	Germany	 	600 29 926.0-08	 	1144003	 	Granted
	12.003011.3a	 	Ireland	 	00904588.1	 	1144003	 	Granted
	12.003011.8a	 	Israel	 	144403	 	144403	 	Granted
	12.003011.8b	 	Israel	 	144558	 	144558	 	Granted
	12.003011.8c	 	Israel	 	144402	 	144402	 	Granted
	12.003011.3a	 	Italy	 	00904588.1	 	1144003	 	Granted
	12.003011.7b	 	Japan	 	2000-594315	 	N/A	 	Abandoned
	12.003011.7c	 	Japan	 	2000-594960	 	N/A	 	Abandoned
	12.003011.3a	 	Netherlands	 	00904588.1	 	1144003	 	Granted
	12.003011.2a	 	PCT	 	US00/01960	 	N/A	 	Expired
	12.003011.2b	 	PCT	 	US00/01961	 	N/A	 	Expired
	12.003011.2c	 	PCT	 	US00/02061	 	N/A	 	Expired
	12.003011.3a	 	Spain	 	00904588.1	 	1144003	 	Granted
	12.003011.3a	 	Switzerland	 	00904588.1	 	1144003	 	Granted
	12.003011.3a	 	United Kingdom	 	00904588.1	 	1144003	 	Granted
	12.003011	 	US	 	09/313,463	 	6,638,727	 	Granted
	12.003011.1	 	US	 	60/117,281	 	N/A	 	Expired
	12.003011.2	 	US	 	10/608,225	 	N/A	 	Abandoned
	12.004011.5	 	Canada	 	2344197	 	2344197	 	Granted
	12.004011.2	 	PCT	 	US99/21378	 	N/A	 	Expired
	12.004011	 	US	 	60/100,853	 	N/A	 	Expired
	12.004011.1	 	US	 	09/397,753	 	6391,026	 	Granted
	12.004011.2	 	US	 	10/144,853	 	6,712.816	 	Granted


 



    	 



    	 



    

 


	Docket No.	 	Country	 	Application No.	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 
	12.005011.2	 	PCT - priority to 60/127,507	 	US99/27060	 	N/A	 	Expired
	12.005011	 	US - priority to 60/127,507	 	09/438,219	 	6,328,709	 	Granted
	12.005011.0	 	US	 	60/108,449	 	N/A	 	Expired
	 	 	US	 	60/127,507	 	N/A	 	Expired
	12.006011	 	AU	 	65062/99	 	774637	 	Granted
	12.006011	 	EPC	 	99953027	 	N/A	 	Abandoned
	12.006011	 	IL	 	142345	 	142340	 	Granted
	12.006011	 	JP	 	2000-573390	 	N/A	 	Abandoned
	12.006011	 	PCT	 	US99/22910	 	N/A	 	Expired
	12.006111	 	US	 	60/102,829	 	N/A	 	Expired
	12.006111	 	US	 	09/410,336	 	N/A	 	Abandoned
	12.006111	 	US	 	09/565,642	 	N/A	 	Abandoned
	12.006011	 	US	 	12/497,521	 	N/A	 	Abandoned
	12.007011.3	 	EPC	 	00903283.0	 	1150602	 	Granted
	12.007011.3	 	France	 	00903283,0	 	1150602	 	Granted
	12.007011.3	 	Germany	 	600 38 603.1	 	600 38 603.1	 	Granted
	12.007011.2	 	PCT	 	US00/00857	 	N/A	 	Expired
	12.007011.3	 	United Kingdom	 	00903283.0	 	1150602	 	Granted
	12.007011	 	US	 	09/482,145	 	6,314,315	 	Granted
	12.007011.1	 	US	 	60/115,787	 	N/A	 	Expired
	12.008011	 	US	 	09/502,404	 	6;642,010	 	Granted
	12.008011.2	 	US	 	10/637,545	 	N/A	 	Abandoned
	12.009011	 	US	 	09/502,206	 	N/A	 	Abandoned
	12.009011.2	 	US	 	10/721,701	 	7,384,418	 	Granted
	12.010011	 	AU	 	2001-259477	 	2001-259477	 	Granted
	12.010011	 	AU	 	2010-201895	 	N/A	 	Lapsed
	12.010011	 	EPC	 	01933007	 	N/A	 	Abandoned
	12.010011	 	PCT	 	US01/14445	 	N/A	 	Expired
	12.011011.4a	 	Australia	 	23939/00	 	762512	 	Granted
	12.011011.4b	 	Australia	 	2003-248404	 	N/A	 	Abandoned
	12.011011.5	 	Canada	 	2356963	 	N/A	 	Abandoned
	12.011011.3	 	EPC	 	99967699.2	 	N/A	 	Abandoned
	12.011011.8	 	Israel	 	144033	 	144033	 	Granted
	12.011011.7	 	Japan	 	2000-591407	 	N/A	 	Abandoned
	12.011011.2	 	PCT	 	US99/31086	 	N/A	 	Expired
	12.011011.0	 	US	 	60/114,048	 	N/A	 	Expired
	12.011011.1	 	US	 	09/473,510	 	6,413,228	 	Granted
	12.011011.2	 	US	 	09/907,581	 	N/A	 	Abandoned
	12.011011.3	 	US	 	09/907,931	 	N/A	 	Abandoned
	12.011011.4	 	US	 	11/880,811	 	N/A	 	Abandoned
	12.012011.4	 	Australia	 	57322/00	 	769853	 	Granted
	12.012011.3	 	EPC	 	00942739.4	 	1185309	 	Granted
	12.012011.3	 	France	 	00942739.4	 	1185309	 	Granted
	12.012011.3	 	Germany	 	600 31 114.7-08	 	1185309	 	Granted
	12.012011.3	 	Ireland	 	00942739.4	 	1185309	 	Granted
	12.012011.8	 	Israel	 	146801	 	146801	 	Granted
	12.012011.3	 	Italy	 	00942739.4	 	1185309	 	Granted


 



    	 



    	 



    

 


	Docket No.	 	Country	 	Application No.	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 
	12.012011.3	 	Netherlands	 	00942739.4	 	1185309	 	Granted
	12.012011.2	 	PCT	 	US00/15993	 	N/A	 	Expired
	12.012011.3	 	Spain	 	00942739.4	 	1185309	 	Granted
	12.012011.3	 	Switzerland	 	00942739.4	 	1185309	 	Granted
	12.012011.3	 	United Kingdom	 	00942739.4	 	1185309	 	Granted
	12.012011	 	US	 	09/590,517	 	6,589,998	 	Granted
	12.012011.1	 	US	 	60/138,693	 	N/A	 	Expired
	12.012011.2	 	US	 	10/425,177	 	N/A	 	Abandoned
	12.013011.4	 	Australia	 	2001-259714	 	N/A	 	Abandoned
	12.013611.3	 	EPC	 	01933276.6	 	N/A	 	Abandoned
	12.013011.7	 	Japan	 	2001-581685	 	N/A	 	Abandoned
	12.013011.2	 	PCT	 	US01/15126	 	N/A	 	Expired
	12.013011	 	US	 	09/852,145	 	6.629,936	 	Granted
	12.013011.0	 	US	 	60/166,877	 	N/A	 	Expired
	12.013011.1	 	US	 	60/289,536	 	N/A	 	Expired
	12.013011.la	 	US	 	60/203,416	 	N/A	 	Expired
	12.013011.2	 	US	 	10/642,585	 	N/A	 	Abandoned
	12.015011.4	 	Australia	 	2002-237838	 	2002-237838	 	Granted
	12.015011.5	 	Australia	 	2008-202312	 	N/A	 	Abandoned
	12.015011.3	 	EPC	 	02704138.3	 	N/A.	 	Abandoned
	12.015011.3	 	Hong Kong	 	04103881.2	 	N/A	 	Abandoned
	12.015011.7	 	Japan	 	2002-572417	 	N/A	 	Abandoned
	12.015011	 	PCT	 	US02/01142	 	N/A	 	Expired
	12.015011	 	US	 	09/800,970	 	6,642,009	 	Granted
	12.015011.1	 	US	 	60/166,100	 	N/A	 	Expired
	12.015011.2	 	US	 	10/639,595	 	N/A	 	Abandoned
	12.015011.3	 	US	 	11/605,758	 	N/A	 	Abandoned
	12.017011.4	 	Australia	 	2001-277214	 	2001-277214	 	Granted
	12.017011.3	 	EPC	 	01955004.5	 	N/A	 	Abandoned
	12.017011.17	 	Hong Kong	 	03107508.7	 	N/A	 	Abandoned
	12.017011.7	 	Japan	 	2002-516621	 	N/A	 	Abandoned
	12.017011.2	 	PCT	 	US01/23761	 	N/A	 	Expired
	12.017011	 	US	 	09/916,647	 	6,673,024	 	Granted
	12.017011.0	 	US	 	60/221,864	 	N/A	 	Expired
	12.017011.1	 	US	 	10/716,704	 	N/A	 	Abandoned
	12.019011.4	 	Australia	 	2001-281161	 	2001-281161	 	Granted
	12.019011.3	 	EPC	 	01959626.1	 	1307746	 	Granted
	12.019011.3	 	France	 	01959626.1	 	1307746	 	Granted
	12.019011.3	 	Germany	 	60127 965.4-08	 	1307746	 	Granted
	12.019011.3	 	Greece	 	01959626.1	 	1307746	 	Granted
	12.019011.17	 	Hong Kong	 	03107628.2	 	HK1055462	 	Granted
	12.019011.4	 	Hong Kong	 	07110674.5	 	N/A	 	Pending
	12.019011.3	 	Ireland	 	01959626.1	 	1307746	 	Granted
	12.019011.7	 	Japan	 	2002-517533	 	N/A	 	Abandoned
	12.019011.3	 	Netherlands	 	01959626.1	 	1307746	 	Granted
	12.019011.2	 	PCT	 	US01/24770	 	N/A	 	Expired
	12.019011.3	 	Spain	 	01959626.1	 	1307746	 	Granted


 



    	 



    	 



    

 


	Docket No.	 	Country	 	Application No.	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 
	12.019011.3	 	Switzerland	 	01959626.1	 	1307746	 	Granted
	12.019011	 	US	 	09/923.791	 	7,132,232	 	Granted
	12.019011.0	 	US	 	60/223,857	 	N/A	 	Expired
	12.019011.1	 	US	 	11/492,392	 	7,405,045	 	Granted
	12.020011	 	EPC	 	02761986	 	1379181	 	Granted (withdrawn)
	12.020011	 	France	 	02761956	 	N/A	 	Abandoned
	12.020011	 	Germany	 	02761986	 	N/A	 	Abandoned
	12.020011	 	Ireland	 	02761986	 	N/A	 	Abandoned
	12.020011	 	PCT	 	US02/09587	 	N/A	 	Expired
	12.020011	 	Spain	 	02761986	 	N/A	 	Abandoned
	12.020011	 	Switzerland	 	02761986	 	N/A	 	Abandoned
	12.020011	 	United Kingdom	 	02761986	 	N/A	 	Abandoned
	12.020011	 	US	 	60/283,637	 	N/A	 	Expired
	12.020011	 	US	 	10/108,993	 	N/A	 	Abandoned
	12.023011.4	 	Australia	 	2002-258542	 	N/A	 	Abandoned
	12.023011.2	 	EPC	 	02728494.2	 	N/A	 	Abandoned
	12.023011.7	 	Japan	 	2002-579023	 	N/A	 	Abandoned
	12.023011.2	 	PCT	 	US02/08232	 	N/A	 	Expired
	12.023011	 	US	 	09/827,371	 	N/A	 	Abandoned
	12.023011.2	 	US	 	10/825,752	 	7,628.765	 	Granted
	12.024011.4	 	Australia	 	2002-258642	 	2002-258642	 	Granted
	12.024011.3	 	EPC	 	02728598.0	 	1379175	 	Granted
	12.024011.3	 	France	 	02728598.0	 	1379175	 	Granted
	12.024011.3	 	Germany	 	02728598.0	 	602 26 584.3	 	Granted
	12.024011.3	 	Hong Kong	 	04103882.1	 	HK1 060838	 	Granted
	12.024011.3	 	Ireland	 	02728598.0	 	1379175	 	Granted
	12.024011.7	 	Japan	 	2002-580813	 	N/A	 	Abandoned
	12.024011.2	 	PCT	 	US02/09583	 	N/A	 	Expired
	12.024011.3	 	United Kingdom	 	02728598.0	 	1379175	 	Granted
	12.024011	 	US	 	10/109,046	 	6,689,070	 	Granted
	12.024011.1	 	US	 	60/283,636	 	N/A	 	Expired
	12.024011.2	 	US	 	10/762,978	 	N/A	 	Abandoned
	12.025011.4a	 	Australia	 	35066/00	 	763173	 	Granted
	12.025011.4b	 	Australia	 	2003-204883	 	2003-204883	 	Granted
	12.025011.4c	 	Australia	 	2006-207852	 	N/A	 	Abandoned
	12.025011.5	 	Canada	 	2364019	 	N/A	 	Abandoned
	12.025011.3	 	EPC	 	00913661.5	 	1165160	 	Granted
	12.025011.4	 	EPC	 	07009685.4	 	N/A	 	Abandoned
	12.025011.3	 	France	 	00913661.5	 	1165160	 	Granted
	12.025011.3	 	Germany	 	00913661.5	 	600 35 861.5	 	Granted
	12.025011.4	 	Hong Kong	 	07112950.6	 	N/A	 	Abandoned
	12.025011.3	 	Ireland	 	00913661.5	 	1165160	 	Granted
	12.025011.8	 	Israel	 	145217	 	N/A	 	Abandoned
	12.025011.3	 	Italy	 	00913661.5	 	1165160	 	Granted
	12.025011.7	 	Japan	 	2000-602328	 	N/A	 	Abandoned
	12.025011.3	 	Netherlands	 	00913661.5	 	1165160	 	Granted
	12.025011.2	 	PCT	 	US00/05142	 	N/A	 	Expired


 



    	 



    	 



    

 


	Docket No.	 	Country	 	Application No.	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 
	12.025011.3	 	Spain	 	00913661.5	 	1165160	 	Granted
	12.025011.3	 	Switzerland	 	00913661.5	 	1165160	 	Granted
	12.025011.3	 	United Kingdom	 	00913661.5	 	1165160	 	Granted
	12.025011.0	 	US	 	60/122,076	 	N/A	 	Expired
	12.025011.1	 	US	 	60/170.997	 	N/A	 	Expired
	12.025011.2	 	US	 	60/143,359	 	N/A	 	Expired
	12.025011.3	 	US	 	60/143,476	 	N/A	 	Expired
	12.025011.4	 	US	 	60/134,613	 	N/A	 	Expired
	12.02500.5	 	US	 	09/506,477	 	6,398,765	 	Granted
	12.025011.6	 	US	 	10/072,911	 	6,585,706	 	Granted
	12.025011.7	 	US	 	10/607,142	 	7,029,462	 	Granted
	12.025011.8	 	US	 	11/302,929	 	7,204,829	 	Granted
	12.026011.4a	 	Australia	 	54414/00	 	775496	 	Granted
	12.026011.4b	 	Australia	 	57679/01	 	762211	 	Granted
	12.026011.5a	 	Canada	 	2372783	 	N/A	 	Abandoned
	12.026011.5b	 	Canada	 	2353193	 	N/A	 	Abandoned
	12.026011.3a	 	EPC	 	00939309.1	 	1179184	 	Granted
	12.026011.3b	 	EPC	 	01306350.8	 	N/A	 	Abandoned
	12.026011.3c	 	EPC	 	07009496.6	 	N/A	 	Abandoned
	12.026011.3a	 	France	 	00939309.1	 	1179184	 	Granted
	12.026011.3a	 	Germany	 	00939309.1	 	600 35 499.7	 	Granted
	12.026011.3a	 	Ireland	 	00939309.1	 	1179184	 	Granted
	12.026011.8a	 	Israel	 	146374	 	146374	 	Granted
	12.026011.8b	 	Israel	 	144514	 	N/A	 	Abandoned
	12.026011.3a	 	Italy	 	00939309.1	 	1179184	 	Granted
	12.026011.7a	 	Japan	 	2000-618733	 	N/A	 	Abandoned
	12.026011.7b	 	Japan	 	2001-226849	 	N/A	 	Abandoned
	12.026011.3a	 	Netherlands	 	00939309.1	 	N/A	 	Abandoned
	12.026011.2	 	PCT	 	US00/13713	 	N/A	 	Expired
	12.026011.3a	 	Spain	 	00939309.1	 	1179184	 	Granted
	12.026011.3a	 	Switzerland	 	00939309.1	 	1179184	 	Granted
	12.026011.3a	 	United Kingdom	 	00939309	 	1179184	 	Granted
	12.026011.1	 	US	 	09/625,399	 	6,610,484	 	Granted
	12.026011.2	 	US	 	10/622,743	 	N/A	 	On appeal
	12.027011	 	Australia	 	2004-308946	 	N/A	 	Abandoned
	12.027011	 	Canada	 	2549790	 	N/A	 	Abandoned
	12.027011	 	China (People’s Republic)	 	200480041801.7	 	N/A	 	Abandoned
	12.027011	 	EPC	 	04815131.0	 	1703923	 	Granted
	12.027011.1	 	EPC	 	08008505.3	 	N/A	 	Abandoned
	12.027011	 	France	 	04815131,0	 	1703923	 	Granted
	12.027011	 	Germany	 	60 2004 013 637.9	 	1703923	 	Granted
	12.027011	 	Hong Kong	 	06114039.8	 	N/A	 	Abandoned
	12.027011	 	India	 	733/MUMNP/2 006	 	N/A	 	Abandoned
	12.027011	 	Italy	 	04815131.0	 	1703923	 	Granted
	12.027011	 	Japan	 	2006-547291	 	N/A	 	Abandoned
	12.027011	 	Korea, Republic of	 	10-2006-7012628	 	N/A	 	Abandoned
	12.027011	 	PCT	 	US04/043015	 	N/A	 	Expired
	12.027011	 	United Kingdom	 	04815131.0	 	1703923	 	Granted


 



    	 



    	 



    

 


	Docket No.	 	Country	 	Application No.	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 
	12.027011.	 	US	 	10/746,128	 	7,229,420	 	Granted-
	12.027011.1	 	US	 	11/504,995	 	N/A	 	Abandoned
	12.033011	 	US	 	10/746,121	 	7,195,601	 	Granted
	12.034011	 	US	 	10/746,117	 	7,276,047	 	Granted
	12.034011.1	 	US	 	11/415,029	 	N/A	 	Abandoned


 



    	 



    	 



    

 


EXHIBIT B-2


 


PATENTS AND PATENT APPLICATIONS NOT BEING
ASSIGNED


 


	Docket No.	 	Country	 	Application No.	 	Patent No.
	12.005011.5	 	Canada	 	2350502	 	N/A
	12.006011	 	US	 	11/705,277	 	N/A
	12.007011.5	 	Canada	 	2360540	 	2360540
	12.008011.3	 	US	 	11/713,495	 	N/A
	12.010011	 	AU	 	2007-200548	 	N/A
	12.010011	 	CA	 	2346048	 	N/A
	12.010011	 	US	 	10/858,086	 	N/A
	12.012011.5	 	Canada	 	2375576	 	N/A
	12.012011.3	 	US	 	11/725,928	 	N/A
	12.014011	 	Australia	 	2002-247262	 	N/A
	12.014011	 	EPC (FR, DE, IE,1T, ES, SE, CH, UK)	 	02715041.6	 	1372671
	12.014011	 	Japan	 	2002-576981	 	N/A
	12.014011	 	US	 	11/203,800	 	N/A
	12.019011.5	 	Australia	 	2007-234568	 	N/A
	12.019011.4	 	EPC	 	07002776.8	 	N/A
	12.019011.3	 	Italy	 	01959626.1	 	1307746
	12.019011.3	 	United Kingdom	 	01959626.1	 	1307746
	12.020011	 	US	 	11/154,170	 	N/A
	12.028011	 	US	 	10/746,940	 	N/A
	12.028011	 	US	 	10/746,950	 	7,494,472


 



    	 



    	 



    

 


EXHIBIT
C


 


PURCHASED
DEVICE MANUFACTURING DOCUMENTATION


 



    	 



    	 



    

 


EXHIBIT
D


 


PURCHASED
DEVICE MARKETING MATERTAL


 



    	 



    	 



    

 


EXHIBIT
E


 


FORM OF
TRADEMARK ASSIGNMENT


 


[Attached]


 



    	 



    	 



    

 


TRADEMARK
ASSIGNMENT


 


This Trademark Assignment (this “Assignment”)
is made effective this 4th day of May, 2011, by and between Hologic, Inc., a corporation organized and existing under the laws
of the state of Delaware, and having a usual place of business at 250 Campus Drive, Marlborough, Massachusetts 01752, United States
(“Assignor”) and Atossa Genetics, Inc., a corporation organized and existing under the’ laws of the State
of Delaware, and having a usual place of business at 4105 E Madison St, Suite 320, Seattle, WA 98112, United States (“Assignee”).


 


WHEREAS, Assignor holds all right, title
and interest in and to the trademarks, service marks and trade names set forth on Schedule A attached hereto and incorporated
herein by reference (the “Marks”);


 


WHEREAS, Assignor and Assignee are parties
to that certain Purchase Agreement, dated as of the date hereof (the “Purchase Agreement”), pursuant to which
Assignor transferred, sold and conveyed to Assignee certain assets of Assignor, including the Marks and the goodwill of the business
symbolized thereby; and


 


WHEREAS, Assignor now wishes to assign the
Marks to Assignee, and Assignee is desirous of acquiring the Marks from Assignor, together with the goodwill of the business symbolized
thereby.


 


NOW, THEREFORE, in consideration of the
premises set forth above and in the Purchase Agreement and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged:


 


Assignor does hereby sell, assign, convey
and transfer unto Assignee and its successors, assigns and legal representatives, Assignor’s entire right, title and interest
in and throughout the world in and to the Marks (including any common law rights that may exist and are associated therewith),
together with the goodwill of the business symbolized thereby and appurtenant thereto, the same to be held and enjoyed by Assignee,
its successors, permitted assigns or legal representatives, together with income, royalties, damages or payments due on or after
the date hereof, including, without limitation, all claims for damages or payments by reason of infringement or unauthorized use
of the Marks, along with the right to sue for past infringements and collect same for Assignee’s sole use and enjoyment.


 


Assignor does hereby authorize the Director
of the United States Patent & Trademark Office, and the empowered official of any country or countries foreign to the United
States whose duty it is to record trademark registrations, applications and title thereto, to record the Marks and title thereto
as the property of Assignee, its successors, assigns or legal representatives in accordance with the terms of this instrument.


 


Assignee and Assignor also agree that multiple
copies of this Assignment may be executed, each of which shall be deemed an original, and each of which shall be valid and binding
upon Assignee and Assignor.


 


[Remainder of page intentionally left
blank]


 



    	 



    	 



    

 


IN WITNESS WHEREOF, Assignor and Assignee
have caused this Assignment to be executed as a sealed instrument by their duly authorized representatives as of the date first
written above.


 


	 	ASSIGNOR: 	Hologic, Inc.
	 	Name:	Lindsay G. McGuiness
	 	Signature:	//s// Lindsay G. McGuiness
	 	Title:	Chief Patent Counsel


 


NOTARIZATION


 


On this 4th day of May,
2011, before me, the undersigned Notary Public, personally appeared Lindsay McGuinness, proved to me through satisfactory
evidence of identification, which was/were drivers license, to be the person whose name is signed on the preceding or attached
document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge
and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of Assignor and executed
this document of his/her own free will.


 


	//s// Theodore R. Allen	 	(Seal)
	Signature of Notary	 	 


 


	 	 	 	THEODORE R. ALLEN	 
	 	 	 	Notary Public	 
	 	 	 	COMMONWEALTH OF	 
	My Commission Expires 	 	 	MASSACHUSETTS	 
	 	 	 	My Commission Expires	 
	 	 	 	November 10, 2017	 


 


	 	ASSIGNEE: 	 
	 	Name:	 
	 	Signature:	 
	 	Title:	 


 


On this ____ day of ___________, 201
, before me, the undersigned Notary Public, personally appeared ________________, proved to me through satisfactory evidence
of identification, which was/were __________________________, to be the person whose name is signed on the preceding or attached
document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge
and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of Assignee and executed
this document of his/her own free will.


 


	 	 	 	(Seal)
	Signature of Notary	 	 	 
	 	 	 	 
	My Commission Expires: 	 	 	 


 



    	 



    	 



    

 


Schedule A


 


Marks


 


	Mark	 	Jurisdiction	 	Registration No.
	FIRSTCYTE	 	United States	 	2,782,866
	 	 	Australia	 	 
	 	 	Japan	 	 
	 	 	Switzerland	 	 
	 	 	Norway	 	 
	 	 	European Union	 	 


 



    	 



    	 



    

 


EXHIBIT
F


 


FORM OF
PATENT ASSIGNMENT


 


[Attached]


 



    	 



    	 



    

 


PATENT ASSIGNMENT


 


WHEREAS, Hologic, Inc., a corporation organized
and existing under the laws of the State of Delaware with principal offices located at 250 Campus Drive, Marlborough, Massachusetts
01752, United States (“ASSIGNOR”), has adopted, used and is using the patents, patent applications, inventions and
know-how (collectively, the “Patents”) on the attached Schedule A and


 


WHEREAS, Atossa Genetics, Inc., a corporation
a corporation organized and existing under the laws of the State of Delaware, U.S.A., and having its place of business at 4105
E Madison St, Suite 320, Seattle, WA 98112, United States (“ASSIGNEE”) is desirous of acquiring said Patents;


 


NOW, THEREFORE, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, said ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE, its
successors, assigns and legal representatives, ASSIGNOR’S entire right, title and interest for all countries in and to: (i)
each of the Patents listed in Schedule A hereof and any patents or patent applications (including non-provisionals, continuations,
divisionals, reissues, reexaminations, extensions, renewals, and substitutions) that claim the benefit of or priority to (under
United States law and/or international convention) one or more of the Patents listed in Schedule A; (ii) any and all of the inventions
which are disclosed and claimed in the Patents; (iii) any and all of the inventions, which are disclosed, but not claimed in any
of the Patents; (iv) all continuations, divisionals, substitutions, renewals, reissues, and all other patents, industrial property
or other related property rights in any and all countries which have been or shall be filed on any of the inventions disclosed
in any of the Patents; (v) all original and reissued patents, industrial property or related documents, which have been or shall
be issued on any such inventions disclosed in any of the Patents; and (vi) all rights to sue and recover for past unlicensed infringements
of the Patents. ASSIGNOR authorizes and requests the Commissioner of Patents and Trademarks of the United States and the empowered
officials of all other governmental and administrative agencies to issue to the ASSIGNEE, its successors, assigns and legal representatives
any and all patents, letters patent or industrial property on the inventions or any inventions disclosed in any of the registrations,
and Patents listed above, in accordance with the terms of this instrument.


 


ASSIGNOR agrees that, upon reasonable request
and without further consideration, at ASSIGNEE’S sole cost and expense, it will sign all lawful papers, make all rightful
oaths and generally assist ASSIGNEE in perfecting and recording titles to the Patents listed in Schedule A throughout the
world.


 


ASSIGNEE shall bear all responsibility and
expense for preparing any instrument of assignment or transfer from ASSIGNOR to ASSIGNEE and for recording the same, any fee or
tax levied thereon, and all prosecution and maintenance costs incurred with respect to the Patents.


 


ASSIGNEE shall have the exclusive right
to bring and maintain actions for, and to settle, release and compromise claims for infringement of Patents listed on Schedule
A occurring prior to the date hereof and to retain the proceeds thereof.


 


[Remainder of page intentionally left
blank]


 



    	 



    	 



    

 


IN WITNESS WHEREOF, Assignor and Assignee
have caused this Assignment to be executed by their duly authorized representatives as of the date first written above:


 


	 	ASSIGNOR: 	Hologic, Inc.
	 	Name:	Lindsay G. McGuiness
	 	Signature:	//s// Lindsay G. McGuiness
	 	Title:	Chief Patent Counsel


 


NOTARIZATION


 


On this 4th day of May,
2011, before me, the undersigned Notary Public, personally appeared Lindsay McGuinness, proved to me through satisfactory
evidence of identification, which was/were drivers license, to be the person whose name is signed on the preceding or attached
document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge
and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of Assignor and executed
this document of his/her own free will.


 


	//s// Theodore R. Allen	(Seal)
	Signature of Notary	 


 


	 	 	 	THEODORE R. ALLEN	 
	 	 	 	Notary Public	 
	 	 	 	COMMONWEALTH OF	 
	My Commission Expires 	 	 	MASSACHUSETTS	 
	 	 	 	My Commission Expires	 
	 	 	 	November 10, 2017	 


 


	 	ASSIGNEE: 	 
	 	Name:	 
	 	Signature:	 
	 	Title:	 


 


On this ____ day of ___________, 201
, before me, the undersigned Notary Public, personally appeared ________________, proved to me through satisfactory evidence
of identification, which was/were __________________________, to be the person whose name is signed on the preceding or attached
document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge
and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of Assignee and executed
this document of his/her own free will.


 


	 	 	 	(Seal)
	Signature of Notary	 	 	 
	 	 	 	 
	My Commission Expires:	 	 	 


 



    	 



    	 



    

 


Schedule A


Patents


	Docket No.	 	Country	 	Application No.	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 
	12.001011.3	 	EPC	 	99917356.0	 	1091685	 	Granted
	12.001011.3	 	France	 	99917356.0	 	1091685	 	Granted
	12.001011.3	 	Germany	 	699 38 898.8	 	1091685	 	Granted
	12.001011.3	 	Ireland	 	99917356.0	 	1091685	 	Granted
	12.001011	 	PCT	 	US99/07589	 	N/A	 	Expired
	12.0010113	 	United Kingdom	 	9991735600	 	1091685	 	Granted
	12.001011	 	US	 	60/080,963	 	N/A	 	Expired
	12.001011.1	 	US	 	09/287,087	 	6336,904	 	Granted
	12.003011.4a	 	Australia	 	26319/00	 	763610	 	Granted
	12.003011.4b	 	Australia	 	26320/00	 	764777	 	Granted
	12.003011.4c	 	Australia	 	27406/00	 	766336	 	Granted
	12,0030I1.4d	 	Australia	 	2003-248031	 	N/A	 	Abandoned
	12.003011.4e	 	Australia	 	2003-259578	 	N/A	 	Abandoned
	12.003011.5a	 	Canada	 	2361122	 	N/A	 	Abandoned
	12.003011.5b	 	Canada	 	2361123	 	N/A	 	Abandoned
	12.003011.5c	 	Canada	 	2358971	 	N/A	 	Abandoned
	12.003011.3a	 	EPC	 	00904588.1	 	1144003	 	Granted
	12.003011.3a	 	EPC	 	00904589.9	 	N/A	 	Abandoned
	12.003011.3a	 	EPC	 	009057753	 	N/A	 	Abandoned
	12.003011.3a	 	France	 	00904588.1	 	1144003	 	Granted
	12.003011.3a	 	Germany	 	600 29 926.0-08	 	1144003	 	Granted
	12.003011.3a	 	Ireland	 	00904588.1	 	1144003	 	Granted
	12.003011.8a	 	Israel	 	144403	 	144403	 	Granted
	12.003011.8b	 	Israel	 	144558	 	144558	 	Granted
	12.003011.8c	 	Israel	 	144402	 	144402	 	Granted
	12.003011.3a	 	Italy	 	00904588.1	 	1144003	 	Granted
	12.003011.7b	 	Japan	 	2000-594315	 	N/A	 	Abandoned
	12.003011.7c	 	Japan	 	2000-594960	 	N/A	 	Abandoned
	12.003011.3a	 	Netherlands	 	00904588.1	 	1144003	 	Granted
	12.003011.2a	 	PCT	 	US00/01960	 	N/A	 	Expired
	12.003011.2b	 	PCT	 	US00/01961	 	N/A	 	Expired
	12.003011.2c	 	PCT	 	US00/02061	 	N/A	 	Expired
	12.003011.3a	 	Spain	 	00904588.1	 	1144003	 	Granted
	12.003011.3a	 	Switzerland	 	00904588.1	 	1144003	 	Granted
	12.003011.3a	 	United Kingdom	 	00904588.1	 	1144003	 	Granted
	12.003011	 	US	 	09/313,463	 	6,638,727	 	Granted
	12.003011.1	 	US	 	60/117,281	 	N/A	 	Expired
	12.003011.2	 	US	 	10/608,225	 	N/A	 	Abandoned
	12.004011.5	 	Canada	 	2344197	 	2344197	 	Granted
	12.004011.2	 	PCT	 	US99/21378	 	N/A	 	Expired
	12.004011	 	US	 	60/100,853	 	N/A	 	Expired
	12.004011.1	 	US	 	09/397,753	 	6391,026	 	Granted
	12.004011.2	 	US	 	10/144,853	 	6,712.816	 	Granted
	12.005011.2	 	PCT - priority to 60/127,507	 	US99/27060	 	N/A	 	Expired


 



    	 



    	 



    

 


	Docket No.	 	Country	 	Application No.	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 
	12.005011	 	US - priority to 60/127,507	 	09/438,219	 	6,328,709	 	Granted
	12.005011.0	 	US	 	60/108,449	 	N/A	 	Expired
	 	 	US	 	60/127,507	 	N/A	 	Expired
	12.006011	 	AU	 	65062/99	 	774637	 	Granted
	12.006011	 	EPC	 	99953027	 	N/A	 	Abandoned
	12.006011	 	IL	 	142345	 	142340	 	Granted
	12.006011	 	JP	 	2000-573390	 	N/A	 	Abandoned
	12.006011	 	PCT	 	US99/22910	 	N/A	 	Expired
	12.006111	 	US	 	60/102,829	 	N/A	 	Expired
	12.006111	 	US	 	09/410,336	 	N/A	 	Abandoned
	12.006111	 	US	 	09/565,642	 	N/A	 	Abandoned
	12.006011	 	US	 	12/497,521	 	N/A	 	Abandoned
	12.007011.3	 	EPC	 	00903283.0	 	1150602	 	Granted
	12.007011.3	 	France	 	00903283,0	 	1150602	 	Granted
	12.007011.3	 	Germany	 	600 38 603.1	 	600 38 603.1	 	Granted
	12.007011.2	 	PCT	 	US00/00857	 	N/A	 	Expired
	12.007011.3	 	United Kingdom	 	00903283.0	 	1150602	 	Granted
	12.007011	 	US	 	09/482,145	 	6,314,315	 	Granted
	12.007011.1	 	US	 	60/115,787	 	N/A	 	Expired
	12.008011	 	US	 	09/502,404	 	6;642,010	 	Granted
	12.008011.2	 	US	 	10/637,545	 	N/A	 	Abandoned
	12.009011	 	US	 	09/502,206	 	N/A	 	Abandoned
	12.009011.2	 	US	 	10/721,701	 	7,384,418	 	Granted
	12.010011	 	AU	 	2001-259477	 	2001-259477	 	Granted
	12.010011	 	AU	 	2010-201895	 	N/A	 	Lapsed
	12.010011	 	EPC	 	01933007	 	N/A	 	Abandoned
	12.010011	 	PCT	 	US01/14445	 	N/A	 	Expired
	12.011011.4a	 	Australia	 	23939/00	 	762512	 	Granted
	12.011011.4b	 	Australia	 	2003-248404	 	N/A	 	Abandoned
	12.011011.5	 	Canada	 	2356963	 	N/A	 	Abandoned
	12.011011.3	 	EPC	 	99967699.2	 	N/A	 	Abandoned
	12.011011.8	 	Israel	 	144033	 	144033	 	Granted
	12.011011.7	 	Japan	 	2000-591407	 	N/A	 	Abandoned
	12.011011.2	 	PCT	 	US99/31086	 	N/A	 	Expired
	12.011011.0	 	US	 	60/114,048	 	N/A	 	Expired
	12.011011.1	 	US	 	09/473,510	 	6,413,228	 	Granted
	12.011011.2	 	US	 	09/907,581	 	N/A	 	Abandoned
	12.011011.3	 	US	 	09/907,931	 	N/A	 	Abandoned
	12.011011.4	 	US	 	11/880,811	 	N/A	 	Abandoned
	12.012011.4	 	Australia	 	57322/00	 	769853	 	Granted
	12.012011.3	 	EPC	 	00942739.4	 	1185309	 	Granted
	12.012011.3	 	France	 	00942739.4	 	1185309	 	Granted
	12.012011.3	 	Germany	 	600 31 114.7-08	 	1185309	 	Granted
	12.012011.3	 	Ireland	 	00942739.4	 	1185309	 	Granted
	12.012011.8	 	Israel	 	146801	 	146801	 	Granted
	12.012011.3	 	Italy	 	00942739.4	 	1185309	 	Granted


 



    	 



    	 



    

 


	Docket No.	 	Country	 	Application No.	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 
	12.012011.3	 	Netherlands	 	00942739.4	 	1185309	 	Granted
	12.012011.2	 	PCT	 	US00/15993	 	N/A	 	Expired
	12.012011.3	 	Spain	 	00942739.4	 	1185309	 	Granted
	12.012011.3	 	Switzerland	 	00942739.4	 	1185309	 	Granted
	12.012011.3	 	United Kingdom	 	00942739.4	 	1185309	 	Granted
	12.012011	 	US	 	09/590,517	 	6,589,998	 	Granted
	12.012011.1	 	US	 	60/138,693	 	N/A	 	Expired
	12.012011.2	 	US	 	10/425,177	 	N/A	 	Abandoned
	12.013011.4	 	Australia	 	2001-259714	 	N/A	 	Abandoned
	12.013611.3	 	EPC	 	01933276.6	 	N/A	 	Abandoned
	12.013011.7	 	Japan	 	2001-581685	 	N/A	 	Abandoned
	12.013011.2	 	PCT	 	US01/15126	 	N/A	 	Expired
	12.013011	 	US	 	09/852,145	 	6.629,936	 	Granted
	12.013011.0	 	US	 	60/166,877	 	N/A	 	Expired
	12.013011.1	 	US	 	60/289,536	 	N/A	 	Expired
	12.013011.la	 	US	 	60/203,416	 	N/A	 	Expired
	12.013011.2	 	US	 	10/642,585	 	N/A	 	Abandoned
	12.015011.4	 	Australia	 	2002-237838	 	2002-237838	 	Granted
	12.015011.5	 	Australia	 	2008-202312	 	N/A	 	Abandoned
	12.015011.3	 	EPC	 	02704138.3	 	N/A.	 	Abandoned
	12.015011.3	 	Hong Kong	 	04103881.2	 	N/A	 	Abandoned
	12.015011.7	 	Japan	 	2002-572417	 	N/A	 	Abandoned
	12.015011	 	PCT	 	US02/01142	 	N/A	 	Expired
	12.015011	 	US	 	09/800,970	 	6,642,009	 	Granted
	12.015011.1	 	US	 	60/166,100	 	N/A	 	Expired
	12.015011.2	 	US	 	10/639,595	 	N/A	 	Abandoned
	12.015011.3	 	US	 	11/605,758	 	N/A	 	Abandoned
	12.017011.4	 	Australia	 	2001-277214	 	2001-277214	 	Granted
	12.017011.3	 	EPC	 	01955004.5	 	N/A	 	Abandoned
	12.017011.17	 	Hong Kong	 	03107508.7	 	N/A	 	Abandoned
	12.017011.7	 	Japan	 	2002-516621	 	N/A	 	Abandoned
	12.017011.2	 	PCT	 	US01/23761	 	N/A	 	Expired
	12.017011	 	US	 	09/916,647	 	6,673,024	 	Granted
	12.017011.0	 	US	 	60/221,864	 	N/A	 	Expired
	12.017011.1	 	US	 	10/716,704	 	N/A	 	Abandoned
	12.019011.4	 	Australia	 	2001-281161	 	2001-281161	 	Granted
	12.019011.3	 	EPC	 	01959626.1	 	1307746	 	Granted
	12.019011.3	 	France	 	01959626.1	 	1307746	 	Granted
	12.019011.3	 	Germany	 	60127 965.4-08	 	1307746	 	Granted
	12.019011.3	 	Greece	 	01959626.1	 	1307746	 	Granted
	12.019011.17	 	Hong Kong	 	03107628.2	 	HK1055462	 	Granted
	12.019011.4	 	Hong Kong	 	07110674.5	 	N/A	 	Pending
	12.019011.3	 	Ireland	 	01959626.1	 	1307746	 	Granted
	12.019011.7	 	Japan	 	2002-517533	 	N/A	 	Abandoned
	12.019011.3	 	Netherlands	 	01959626.1	 	1307746	 	Granted
	12.019011.2	 	PCT	 	US01/24770	 	N/A	 	Expired


 



    	 



    	 



    

 


	Docket No.	 	Country	 	Application No.	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 
	12.019011.3	 	Spain	 	01959626.1	 	1307746	 	Granted
	12.019011.3	 	Switzerland	 	01959626.1	 	1307746	 	Granted
	12.019011	 	US	 	09/923.791	 	7,132,232	 	Granted
	12.019011.0	 	US	 	60/223,857	 	N/A	 	Expired
	12.019011.1	 	US	 	11/492,392	 	7,405,045	 	Granted
	12.020011	 	EPC	 	02761986	 	1379181	 	Granted (withdrawn)
	12.020011	 	France	 	02761956	 	N/A	 	Abandoned
	12.020011	 	Germany	 	02761986	 	N/A	 	Abandoned
	12.020011	 	Ireland	 	02761986	 	N/A	 	Abandoned
	12.020011	 	PCT	 	US02/09587	 	N/A	 	Expired
	12.020011	 	Spain	 	02761986	 	N/A	 	Abandoned
	12.020011	 	Switzerland	 	02761986	 	N/A	 	Abandoned
	12.020011	 	United Kingdom	 	02761986	 	N/A	 	Abandoned
	12.020011	 	US	 	60/283,637	 	N/A	 	Expired
	12.020011	 	US	 	10/108,993	 	N/A	 	Abandoned
	12.023011.4	 	Australia	 	2002-258542	 	N/A	 	Abandoned
	12.023011.2	 	EPC	 	02728494.2	 	N/A	 	Abandoned
	12.023011.7	 	Japan	 	2002-579023	 	N/A	 	Abandoned
	12.023011.2	 	PCT	 	US02/08232	 	N/A	 	Expired
	12.023011	 	US	 	09/827,371	 	N/A	 	Abandoned
	12.023011.2	 	US	 	10/825,752	 	7,628.765	 	Granted
	12.024011.4	 	Australia	 	2002-258642	 	2002-258642	 	Granted
	12.024011.3	 	EPC	 	02728598.0	 	1379175	 	Granted
	12.024011.3	 	France	 	02728598.0	 	1379175	 	Granted
	12.024011.3	 	Germany	 	02728598.0	 	602 26 584.3	 	Granted
	12.024011.3	 	Hong Kong	 	04103882.1	 	HK1 060838	 	Granted
	12.024011.3	 	Ireland	 	02728598.0	 	1379175	 	Granted
	12.024011.7	 	Japan	 	2002-580813	 	N/A	 	Abandoned
	12.024011.2	 	PCT	 	US02/09583	 	N/A	 	Expired
	12.024011.3	 	United Kingdom	 	02728598.0	 	1379175	 	Granted
	12.024011	 	US	 	10/109,046	 	6,689,070	 	Granted
	12.024011.1	 	US	 	60/283,636	 	N/A	 	Expired
	12.024011.2	 	US	 	10/762,978	 	N/A	 	Abandoned
	12.025011.4a	 	Australia	 	35066/00	 	763173	 	Granted
	12.025011.4b	 	Australia	 	2003-204883	 	2003-204883	 	Granted
	12.025011.4c	 	Australia	 	2006-207852	 	N/A	 	Abandoned
	12.025011.5	 	Canada	 	2364019	 	N/A	 	Abandoned
	12.025011.3	 	EPC	 	00913661.5	 	1165160	 	Granted
	12.025011.4	 	EPC	 	07009685.4	 	N/A	 	Abandoned
	12.025011.3	 	France	 	00913661.5	 	1165160	 	Granted
	12.025011.3	 	Germany	 	00913661.5	 	600 35 861.5	 	Granted
	12.025011.4	 	Hong Kong	 	07112950.6	 	N/A	 	Abandoned
	12.025011.3	 	Ireland	 	00913661.5	 	1165160	 	Granted
	12.025011.8	 	Israel	 	145217	 	N/A	 	Abandoned
	12.025011.3	 	Italy	 	00913661.5	 	1165160	 	Granted
	12.025011.7	 	Japan	 	2000-602328	 	N/A	 	Abandoned


 



    	 



    	 



    

 


	Docket No.	 	Country	 	Application No.	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 
	12.025011.3	 	Netherlands	 	00913661.5	 	1165160	 	Granted
	12.025011.2	 	PCT	 	US00/05142	 	N/A	 	Expired
	12.025011.3	 	Spain	 	00913661.5	 	1165160	 	Granted
	12.025011.3	 	Switzerland	 	00913661.5	 	1165160	 	Granted
	12.025011.3	 	United Kingdom	 	00913661.5	 	1165160	 	Granted
	12.025011.0	 	US	 	60/122,076	 	N/A	 	Expired
	12.025011.1	 	US	 	60/170.997	 	N/A	 	Expired
	12.025011.2	 	US	 	60/143,359	 	N/A	 	Expired
	12.025011.3	 	US	 	60/143,476	 	N/A	 	Expired
	12.025011.4	 	US	 	60/134,613	 	N/A	 	Expired
	12.02500.5	 	US	 	09/506,477	 	6,398,765	 	Granted
	12.025011.6	 	US	 	10/072,911	 	6,585,706	 	Granted
	12.025011.7	 	US	 	10/607,142	 	7,029,462	 	Granted
	12.025011.8	 	US	 	11/302,929	 	7,204,829	 	Granted
	12.026011.4a	 	Australia	 	54414/00	 	775496	 	Granted
	12.026011.4b	 	Australia	 	57679/01	 	762211	 	Granted
	12.026011.5a	 	Canada	 	2372783	 	N/A	 	Abandoned
	12.026011.5b	 	Canada	 	2353193	 	N/A	 	Abandoned
	12.026011.3a	 	EPC	 	00939309.1	 	1179184	 	Granted
	12.026011.3b	 	EPC	 	01306350.8	 	N/A	 	Abandoned
	12.026011.3c	 	EPC	 	07009496.6	 	N/A	 	Abandoned
	12.026011.3a	 	France	 	00939309.1	 	1179184	 	Granted
	12.026011.3a	 	Germany	 	00939309.1	 	600 35 499.7	 	Granted
	12.026011.3a	 	Ireland	 	00939309.1	 	1179184	 	Granted
	12.026011.8a	 	Israel	 	146374	 	146374	 	Granted
	12.026011.8b	 	Israel	 	144514	 	N/A	 	Abandoned
	12.026011.3a	 	Italy	 	00939309.1	 	1179184	 	Granted
	12.026011.7a	 	Japan	 	2000-618733	 	N/A	 	Abandoned
	12.026011.7b	 	Japan	 	2001-226849	 	N/A	 	Abandoned
	12.026011.3a	 	Netherlands	 	00939309.1	 	N/A	 	Abandoned
	12.026011.2	 	PCT	 	US00/13713	 	N/A	 	Expired
	12.026011.3a	 	Spain	 	00939309.1	 	1179184	 	Granted
	12.026011.3a	 	Switzerland	 	00939309.1	 	1179184	 	Granted
	12.026011.3a	 	United Kingdom	 	00939309	 	1179184	 	Granted
	12.026011.1	 	US	 	09/625,399	 	6,610,484	 	Granted
	12.026011.2	 	US	 	10/622,743	 	N/A	 	On appeal
	12.027011	 	Australia	 	2004-308946	 	N/A	 	Abandoned
	12.027011	 	Canada	 	2549790	 	N/A	 	Abandoned
	12.027011	 	China (People’s Republic)	 	200480041801.7	 	N/A	 	Abandoned
	12.027011	 	EPC	 	04815131.0	 	1703923	 	Granted
	12.027011.1	 	EPC	 	08008505.3	 	N/A	 	Abandoned
	12.027011	 	France	 	04815131,0	 	1703923	 	Granted
	12.027011	 	Germany	 	60 2004 013 637.9	 	1703923	 	Granted
	12.027011	 	Hong Kong	 	06114039.8	 	N/A	 	Abandoned
	12.027011	 	India	 	733/MUMNP/2 006	 	N/A	 	Abandoned
	12.027011	 	Italy	 	04815131.0	 	1703923	 	Granted
	12.027011	 	Japan	 	2006-547291	 	N/A	 	Abandoned


 



    	 



    	 



    

 


	Docket No.	 	Country	 	Application No.	 	Patent No.	 	Status
	 	 	 	 	 	 	 	 	 
	12.027011	 	Korea, Republic of	 	10-2006-7012628	 	N/A	 	Abandoned
	12.027011	 	PCT	 	US04/043015	 	N/A	 	Expired
	12.027011	 	United Kingdom	 	04815131.0	 	1703923	 	Granted
	12.027011.	 	US	 	10/746,128	 	7,229,420	 	Granted-
	12.027011.1	 	US	 	11/504,995	 	N/A	 	Abandoned
	12.033011	 	US	 	10/746,121	 	7,195,601	 	Granted
	12.034011	 	US	 	10/746,117	 	7,276,047	 	Granted
	12.034011.1	 	US	 	11/415,029	 	N/A	 	Abandoned


 



    	 



    	 



    

 


EXHIBIT
G


 


In April 2011 Atossa Genetics, Inc. acquired from Hologic, Inc.
all of the ownership rights to the US Trademark, FirstCyte, the 23 US issued patents and 84 issued assign counterparts (in Europe,
France, Germany, Ireland, United Kingdom, Australia, Canada, Israel, Italy, The Netherlands, Spain, and Switzerland) covering the
manufacture, use, and sale of the FirstCyteTM Breast Aspirator, the Micro-Stylet Dilator, and the Microcatheter for ductal
lavage, the related manufacturing documentation, and the related regulatory documentation, including the FDA marketing authorization
for these medical devices. The FDA cleared indications for use of the Breast Aspirator is to elicit fluid from multiple ductal
orifices for subsequent cytological evaluation and/or to identify ductal orifices for subsequent cannulation with the microcatheter.
The FDA cleared indications for use of the Micro-Stylet Dilator is to dilate breast milk ducts prior to enhanced radiography (i.e.,
ductography) or ductal lavage procedures. The FDA cleared indications for use of the microcatheter is to perform contrast enhanced
radiography of breast milk ducts. It may also be used for the collection of cells and/or fluid for cytological analysis.


 


Atossa paid an up-front fee and is obliged to pay patent-based
royalties on aggregate net sales in the countries with issued patents.


 


[Attached]


 






    	 



    	 



    



   


May 5, 2011


Dr. Steven C Quay, MD, PhD, FCAP


Chairman, CEO, and President


Atossa Genetics, Inc.


4105 E. Madison Street, Suite 320


Seattle, Washington 98112


 


Re:      Atossa Genetics Purchase Agreement


 


Dear Dr. Quay,


 


Enclosed please find two copies of the Asset Purchase Agreement
duly executed by Hologic, Inc.





Please note that Atossa Genetics needs to execute the Bill of
Sale as well as the Patent and Trademark Assignments. I have provided one copy of the Patent and Trademark assignments for your
signature since Hologic does not need an executed copy. Once executed, please return one copy (the one without the signed patent
and trademark assignments) of the APA to my attention. Payment of the upfront fee should be remitted to the following:


 





[****]


[****]


[****]


[****]


 


As mentioned in our phone conversation, I will be sending you
the DHF files directly to your attention sometime next week and will be transferring the patent files to your attorneys once I
have their contact information.


 


With best regards,


 


	//s// Ted Allen	 


Ted Allen


Senior Intellectual Property Counsel


Legal Department


Hologic


250 Campus Drive


Marlborough, MA 01752


phone: (508) 263-8490


 





 



    	 



    	 



    

 


May 5, 2011


Dr. Steven C Quay, MD, PhD, FCAP


Chairman, CEO, and President


Atossa Genetics, Inc.


4105 E. Madison Street, Suite 320


Seattle, Washington 98112


 


Re: Atossa Genetics Purchase Agreement


 


Dear Dr. Quay,


 


Enclosed please find two copies of the Asset Purchase Agreement
duly executed by Hologic, Inc.





Please note that Atossa Genetics needs to execute the Bill of
Sale as well as the Patent and Trademark Assignments. I have only provided one copy of the Patent and Trademark assignments for
your signature since Hologic does not need an executed copy. Once executed, please return one copy (the one without the signed
patent and trademark assignments) of the APA to my attention. Payment of the upfront fee should be remitted to the following:


 


[****]


[****]


[****]


[****]


 


As mentioned in our phone conversation, I will be sending you
the DHF files directly to your attention sometime next week and will be transferring the patent files to your attorneys once I
have their Contact information.


With best regards,


 


	//s// Ted Allen	 


Ted Allen


Senior Intellectual Property Counsel


Legal Department


Hologic


250 Campus Drive


Marlborough, MA 01752


phone: (508) 263-8490


 





 



    	 



    	 



    

 


Chase
Online


 


Wire Money -
Step 4 of 4


 


Wire Scheduled
in US Dollars


 


Your
wire is scheduled. To check its status, click “Payments and Transfers” below,
then select “See Wire Activity” from the Wire Transfers tab. 


 





	Wire To	Wire From	Wire Amount	Wire Date	Transaction Number
	[****]	[****]	[****]	[****]	[****]